Celgene products drive BeiGene 4Q revenue gains

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) reported its 4Q18 earnings late Feb. 27 with revenue gains driven by its in-licensed products from Celgene Corp. (NASDAQ:CELG).

BeiGene's portfolio includes Chinese rights to cancer drugs Abraxane nab-paclitaxel, Revlimid lenalidomide and Vidaza azacitidine from Celgene, which BeiGene

Read the full 413 word article

User Sign In